

Supplemental Online Content

Cox LS, Nollen NL, Mayo MS, et al. Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers. *JAMA*. Published online June 14, 2022. doi:10.1001/jama.2022.8274

Supplement 2. eTable 1. Verified 7-day point prevalence smoking abstinence over time by treatment and smoking level (cigarettes/day)

eTable 2. Week 26 self-reported and verified 7-day point prevalence smoking abstinence

eFigure 1. Self-reported medication adherence over time by treatment

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1. Verified 7-day point prevalence smoking abstinence over time by treatment and smoking level (cigarettes/day)

Week	Smoking Level cigarettes/day	n	Smoking Abstinence (%)		Difference (95% CI)	Odds Ratio (95% CI)	P value	Interaction P value
			Varenicline n = 300	Placebo n = 200				
4	Overall	500	48/300 (16.0%)	10/200 (5.0%)	11.0% (5.9%-16.1%)	3.6 (1.8-7.3)	<.001	0.36
	Light 1-10	260	34/154 (22.0%)	6/106 (5.7%)	16.3% (8.4%-14.2%)	4.7 (1.9-11.7)	<.001	
	Heavy >10	240	14/146 (9.6%)	4/94 (4.3%)	5.3% (-1.0%-11.6%)	2.4 (.8-7.5)	0.13	
12	Overall	500	56/300 (18.7%)	14/200 (7.0%)	11.7% (6.0%-17.7%)	3.0 (1.7-5.6)	<.001	0.96
	Light 1-10	260	34/154 (22.1%)	9/106 (8.5%)	13.6% (5.2%-22.0%)	3.0 (1.4-6.7)	0.004	
	Heavy >10	240	22/146 (15.1%)	5/94 (5.3%)	9.8% (2.4%-17.2%)	3.1 (1.1-8.6)	0.02	
16	Overall	500	54/300 (18.0%)	13/200 (6.5%)	11.5% (6.0%-17.0%)	3.2 (1.7-6.0)	<.001	0.62
	Light 1-10	260	32/154 (20.8%)	9/106 (8.5%)	12.3% (4.0%-20.1%)	2.8 (1.3-6.2)	0.008	
	Heavy >10	240	22/146 (15.1%)	4/94 (4.3%)	10.8% (3.7%-17.9%)	4.0 (1.3-12.0)	0.009	
26	Overall	500	47/300 (15.7%)	13/200 (6.5%)	9.2% (3.8%-14.5%)	2.7 (1.4-5.1)	0.002	0.77
	Light 1-10	260	33/154 (21.4%)	9/106 (8.5%)	12.9% (4.5%-21.3%)	2.9 (1.3-6.4)	0.005	
	Heavy >10	240	14/146 (9.6%)	4/94 (4.3%)	5.3% (-1.0%-11.6%)	2.4 (.8-7.5)	0.13	

Cotinine verified (≤ 15 ng/mL). Participants with missing data were imputed as smoking.

eTable 2. Week 26 self-report and verified 7-day point prevalence smoking abstinence

	Treatment		P value
	Varenicline	Placebo	
A) Number of participants randomized	300	200	
B) Number of participants who completed Week 26 visit (B/A)	267 (89.0%)	174 (87.0%)	NA
C) Self-reported completers only abstinence at Week 26 (C/B)	114 (42.7%)	64 (36.8%)	NA
D) Verification samples obtained at Week 26 (D/C)	109 (95.6%)	62 (96.9%)	NA
E) Verified abstinence for completers only (E/B)	47 (17.6%)	13 (7.5%)	0.002
F) Verified abstinence using Russel Standard* (F/A)	47 (15.7%)	13 (6.5%)	0.002
G) Verified abstinence using Last Observation Carried Forward	71 (23.7%)	19 (9.5%)	<0.001
H) Verified abstinence using Multiple Imputation**	69.2 (23.1%)	27.8 (13.9%)	0.02
*Participants with missing data imputed as smoking			
**Average of 100 imputations assuming monotonic logistic regression with treatment and smoking level			

eFigure 1. Self-reported medication adherence over time by treatment

